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Endoscopic ultrasonography (EUS) technology has undergone a great deal of progress along with 
the color and power Doppler imaging, three-dimensional imaging, electronic scanning, tissue 
harmonic imaging, and elastography, and one of the most important developments is the ability 
to acquire contrast-enhanced images. The blood flow in small vessels and the parenchymal 
microvasculature of the target lesion can be observed non-invasively by contrast-enhanced 
EUS (CE-EUS). Through a hemodynamic analysis, CE-EUS permits the diagnosis of various 
gastrointestinal diseases and differential diagnoses between benign and malignant tumors. 
Recently, mechanical innovations and the development of contrast agents have increased the 
use of CE-EUS in the diagnostic field, as well as for the assessment of the efficacy of therapeutic 
agents. The advances in and the current status of CE-EUS are discussed in this review.
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Introduction
Matsuda and Yabuuchi [1] first introduced the concept of contrast-enhanced abdominal 
ultrasonography (CE-US) in 1986. With the use of an intra-arterial infusion of carbon dioxide as the 
contrast material, CE-US had diagnostic utility because the signal emitted by the CO2 microbubbles 
was detected in real time during fundamental B-mode US. Kato et al. [2] first introduced contrast-
enhanced endoscopic US (CE-EUS) with the use of an intra-arterial CO2 infusion. However, a limitation 
of these methods was that US was only possible during an angiographic examination. In the mid-
1990s, EUS with a color/power Doppler function became possible, and the development of sonicated 
serum albumin, injected into a peripheral vein, enabled enhanced US, acquiring images without 
angiography [3-5]. The development of CO2 microbubbles and the progress of technical innovations, 
such as harmonic imaging, have resulted in improvements in the visualization of target lesions, 
increasing the utility of CE-EUS. Harmonic imaging visualizes microvessels and parenchymal perfusion 
by decreasing artifacts, such as blooming, in US [6].
In general, CE-EUS is categorized into two types: CE-EUS with the Doppler method (CE-EUS-D) 
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and CE-EUS with harmonic imaging (CE-EUS-H). CE-EUS-D helps 
to distinguish between vascular-rich and hypovascular areas of 
a target lesion. CE-EUS-H provides a more detailed vasculature 
image of the target lesion [7]. Due to the differences between the 
two modes, information about the target lesion can be obtained 
and characterized depending on the purpose. Furthermore, the 
contrast-enhanced images acquired with CE-EUS can be subjected 
to quantitative analyses using Inflow Time Mapping (Hitachi Aloka 
Medical, Tokyo, Japan) and time-intensity curve (TIC) patterns to 
objectively characterize the target lesions [7]. Additionally, three-
dimensional (3D) CE-EUS can provide positive information regarding 
the relationship between the target location and the locations of 
adjacent organs and blood vessels via 3D reconstructed images 
[8-10]. Such progress in the development of CE-EUS has enabled 
the characterization of microvascularization, which can be used in 
the differential diagnosis of benign and malignant focal lesions as 
well as to improve the staging guidance for therapeutic procedures. 
In this review, we describe the current status of CE-EUS and the 
direction of future developments.
Contrast Agents
Contrast agents, used in CE-EUS and injected into peripheral veins, 
are an important factor in enhancing ultrasonograms. Contrast 
agents generally consist of gas-filled microbubbles, encapsulated by 
a phospholipid or albumin shell. They are classified into three types 
on the basis of their capability for transpulmonary passage and their 
half-life in the human body [7,11]. Commercially available contrast 
agents are listed in Table 1. The first ultrasound contrast agent (UCA) 
was Levovist (Bergkamen, Germany), consisting of microbubbles of 
air, covered by galactose and palmitic acid [12]. When this agent is 
used, contrast-enhanced harmonic imaging requires high acoustic 
power to oscillate or break the Levovist microbubbles. However, 
the EUS instrument is equipped with only a small transducer, 
and therefore, the transmission signals are too low to oscillate or 
break the Levovist microbubbles. In contrast, second-generation 
contrast agents for US, such as SonoVue (Milan, Italy), Sonazoid 
(Little Chalfont, UK), and Definity (N. Billerica, MA, USA), can be 
oscillated or even broken with a small transducer [12]. Due to the 
limited acoustic power of EUS, second-generation agents are more 
appropriate for EUS [13]. The only third-generation agent currently 
available is Echogen (Washington, DC, USA), which undergoes a 
phase shift from liquid to gas at body temperature [14]. The contrast 
agents that are currently in use are relatively safe, and no severe or 
long-lasting adverse effects have yet been reported in humans [11].
Clinical Applications: Diagnosis
Through a hemodynamic analysis with enhanced images obtained 
using contrast agents, CE-EUS can be used in the differential 
diagnosis of various gastrointestinal diseases. Topics that are being 
researched in conjunction with various diseases are discussed below.
Pancreatic Disease
Because EUS can acquire high-resolution images of the pancreas, 
it is considered a highly sensitive method for evaluating and 
diagnosing pancreatic lesions, when compared with other imaging 
modalities [15,16]. However, EUS has limitations in evaluating 
intratumoral vascular structures or enhancement patterns in the 
characterization of pancreatic lesions because it lacks enhancing 
Table 1. Contrast agents for ultrasonography 
Contrast agents Composition Manufacturer
First generation
    Albunex 5% Sonicated serum 
albumin with stabilized 
microbubbles
Mallinckrodt 
Pharmaceuticals 
(Hazelwood, MO, USA)
    Echovist 
    (SHU 454)
Standardized microbubbles 
with galactose shell
Schering (Bergkamen, 
Germany)
    Levovist 
    (SHU 508)
Stabilized, standardized 
microbubbles with 
galactose, 0.1% palmitic 
acid shell
Schering
    Myomap Albumin shell Quadrant 
(Nottingham, UK)
    Qantison Albumin shell Quadrant
    Sonavist Cyanoacrylate shell Schering
Second generation
    Definity/luminity C3F8 with lipid stabilizer 
shell
Bristol-Myers Squibb 
Medical Imaging (N. 
Billerica, MA, USA)
    Sonazoid C4F10 with lipid stabilizer 
shell
GE Healthcare (Little 
Chalfont, UK)
    Imagent-imavist C6F14 with lipid stabilizer 
shell
Alliance (San Diego, 
CA, USA)
    Optison C3F8 with denatured human 
albumin shell
GE Healthcare
    Bisphere/
    cardiosphere
Polylactide-coglycolide 
shell with albumin overcoat
Commercially 
unavailable
    SonoVue SF6 gas with lipid stabilizer 
shell
Bracco (Milan, Italy)
    AI700/imagify C4F10 gas core stabilized 
with polymer shell
Acusphere (Lexington, 
KY, USA)
Third generation
    Echogen Dodecafluoropentane 
liquid in phase shift colloid 
emulsion
Sonus Pharmaceuticals 
(Washington, DC, USA)
Modified from Reddy et al. [11].
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technology. To overcome the limitations of EUS, CE-EUS evaluates 
vascularity using contrast agents to characterize the lesion(s) 
[17-27]. In a meta-analysis, the sensitivity and the specificity of 
differentially diagnosing pancreatic adenocarcinoma using CE-EUS 
were reported to be 94% and 89%, respectively [20]. CE-EUS helps 
in visualizing the microvasculature of a pancreatic lesion to permit 
the characterization of intertumoral structures. This characterization 
can help in the diagnosis of pancreatic ductal adenocarcinoma in 
difficult cases by permitting the observation of hypovascularity, one 
of the signs of ductal adenocarcinoma [6,17] (Fig. 1). In particular, 
the utility of CE-EUS has been reported to include differentiation of 
focal pancreatitis and carcinomas [4,28,29], preoperative localization 
of pancreatic endocrine tumors [30,31], differentiation of mural 
nodules in intraductal papillary mucinous neoplasms, and detection 
of malignant transformations [32,33] (Fig. 2). CE-EUS images 
showed irregular vascularization with only arterial and no venous 
vessels in pancreatic cancer but regular vascularization with the 
detection of venous vessels in focal pancreatitis [4]. This difference 
may be attributed to the relatively high pressure inside a ductal 
adenocarcinoma of the pancreas due to the surrounding fibrous 
tissues. Pancreatic cancer has been shown to be a hypoperfused 
lesion, in comparison with the surrounding normal pancreatic 
parenchyma, but an inflammatory mass has been demonstrated as 
a hyperperfused or isoperfused lesion in CE-EUS [28]. Furthermore, 
various approaches have been proposed for differentiating between 
pancreatic adenocarcinoma and pancreatic disease. Vascularity 
can be analyzed quantitatively by generating TIC while performing 
CE-EUS [7,18,34,35]. Maximum intensity, accumulated intensity 
during observation, intensity reduction rate, and the ratio between 
the uptake by the mass and the uptake by the surrounding 
parenchyma are measured through quantitative analyses, using 
TIC, and are useful in differentiating autoimmune pancreatitis, 
pseudotumors, neuroendocrine tumors, and carcinomas [18,34-36]. 
The maximal intensity and the maximal accumulated intensity (peak 
intensity minus base intensity before contrast injection) of pancreatic 
carcinoma were significantly lower than in autoimmune pancreatitis 
[35]. The echo intensity reduction rate from the peak at 1 minute 
was greatest in pancreatic cancer, followed by mass-forming 
pancreatitis, autoimmune pancreatitis, and neuroendocrine tumor 
[34]. The contrast uptake levels in pancreatic adenocarcinoma and 
chronic pancreatitis were significantly lower than in the surrounding 
tissue. However, the contrast uptake ratio compared with the 
surrounding tissue in a pancreatic ductal adenocarcinoma was 
significantly lower than in chronic pancreatitis [18]. In another study, 
the signal intensity compared with the parenchyma and maximal 
intensity in pancreatic adenocarcinoma was lower than in chronic 
pseudotumoral pancreatitis, while the time to peak was significantly 
greater in pancreatic carcinoma than in pseudotumoral pancreatitis 
[36]. CE-EUS can also be used for T-staging of pancreatobiliary 
carcinomas by observing the invasion at the portal vein more 
accurately than with EUS [37].
While EUS-guided fine-needle aspiration (EUS-FNA) has assumed 
an important role in the pathological diagnosis of pancreatic 
masses, it sometimes fails when used to identify diffusely infiltrating 
pancreatic carcinoma, particularly in patients with chronic 
pancreatitis or a recent episode of acute pancreatitis [38]. In such 
Fig. 1. Typical contrast-enhanced harmonic endoscopic ultrasonography (EUS) image of pancreatic carcinoma.
A. Conventional EUS shows a hypoechoic lesion (arrowheads) with an indistinct margin in the head of the pancreas. B. Contrast-enhanced 
harmonic EUS reveals the lesion as a hypovascular heterogeneous mass with the vessels (arrows) protruding into the cancer.
A B
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cases, CE-EUS can be useful for observing the lesion and finding a 
suitable target lesion for EUS-FNA [25,27,39]. In certain studies, 
CE-EUS has been reported to complement EUS-FNA by assisting in 
the differentiation of a pancreatic adenocarcinoma that had been 
overlooked as a false negative while using EUS-FNA. However, there 
is disagreement as to whether CE-EUS can serve sufficiently as a 
complete replacement for EUS-FNA [17,27]. CE-EUS may serve as 
a complementary tool for EUS-FNA in difficult situations due to an 
intervening vessel or anticoagulation therapy.
Gallbladder
CE-EUS can facilitate the identification of the depth of cancer 
invasion in the diagnosis of gallbladder (GB) cancer. By enhancing 
the first and the third layer of the GB wall, we can improve the 
resolution between the GB wall structure and a cancerous lesion, 
assisting in T-staging by differentiating between T1b and T1a tumors 
with greater accuracy [7,40] (Fig. 3). The depth of tumor infiltration 
was determined according to the TNM classification, as follows: T1, 
hypoechoic tumor invades the first (T1a) or the second layer (T1b); 
and T2, hypoechoic tumor invades the third hyperechoic layer with 
no extension beyond the third layer or into the liver. CE-EUS can 
show a three-layer structure consisting of hyperechoic, hypoechoic, 
and hyperechoic layers from the GB luminal side. The echogenic first 
and third layers are enhanced and the intactness of the three-layer 
structure can be distinguished by CE-EUS. In one study, the accuracy 
of EUS in depicting the depth of tumor invasion was 78.6%, which 
is lower than the 92.9% accuracy of CE-EUS [40]. Furthermore, 
CE-EUS can not only differentiate between infiltrating and exophytic 
GB cancer but also between benign GB diseases, including chronic 
cholecystitis, which exhibit three intact GB layers, and cholesterol 
polyps [3]. Moreover, CE-EUS can facilitate the differentiation of 
GB adenoma and cholesterol polyps according to the homogeneity 
and size of the GB polyps and their enhancement patterns [41] 
(sensitivity, 75%; specificity, 66.6%) (Fig. 4); most adenomas show 
homogeneous enhancement, while the cholesterol polyps show 
heterogeneous enhancement patterns.
Gastrointestinal Tract Disease
Through the enhancement of the third and the fifth layer of the 
esophageal and gastric walls, CE-EUS can assist in the evaluation of 
the depth of invasion of esophageal and gastric adenocarcinoma, 
with greater accuracy (90%) than EUS (76.7%) [42,43]. Furthermore, 
in terms of CE-EUS with TIC, the echo intensity of gastrointestinal 
stromal tumors (GIST) can assist in differentiation because 
Fig. 2. Image of neuroendocrine tumor on contrast-enhanced harmonic endoscopic ultrasonography (EUS).
A. Conventional EUS demonstrates a hypoechoic lesion (arrowheads) with a round shape and a distinct margin in the body of the pancreas. B. 
Contrast-enhanced harmonic EUS shows the lesion as a rather hypervascular heterogeneous mass with a clear margin and vessels protruding 
into the mass (arrows). In the arterial phase, the lesion was enhanced as a hypervascular homogeneous mass; this difference could enable 
the viewer to distinguish a neuroendocrine tumor from a ductal carcinoma in the pancreas.
A B
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Fig. 3. Application of contrast-enhanced harmonic endoscopic ultrasonography (EUS) in the staging of gallbladder cancer.
A. Conventional EUS shows a solid lesion (arrowheads) in the gallbladder. The depth of gallbladder wall invasion is not clearly seen. B. The 
first and third layer of the gallbladder were enhanced by contrast-enhanced harmonic EUS, and the depth of invasion can be identified more 
clearly. Because the first layer (arrowhead) appears to be broken without the discontinuity of the third layer (arrow), the stage was diagnosed 
as T2, which was pathologically confirmed after surgery.
A B
Fig. 4. Enhancement patterns of contrast-enhanced endoscopic ultrasonography (EUS) of gallbladder adenoma and cholesterol polyp.
A. Gallbladder adenoma shows a lobulated contour and a homogeneous enhancement after the injection of the contrast agent. B. 
Cholesterol polyp shows a rather heterogeneous enhancement due to lipid-laden macrophages and the presence of few microvessels with a 
heterogeneous distribution.
A B
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54]. CE-EUS with microspheres monitors the altered pancreatic 
perfusion of an ablated pancreatic lesion, allowing the detection of 
the vascularity at the necrosis site, which can be useful in follow-up 
with a post-ablation treatment [55].
Tumor blood flow is generally associated with metastatic 
potential and poor prognosis [11]. The quantity of vascular signals, 
measured with CE-US, has been reported to be useful in the early 
assessment and monitoring of the efficacy of antiangiogenic agents 
for pancreatic ductal carcinoma before morphological changes 
occur [56]. The quantity of vascular signals detected from pancreatic 
ductal carcinoma by CE-US correlated with tumor characteristics and 
vascular endothelial growth factor (VEGF) expression [57]. The rate 
of hepatic metastasis and the VEGF expression were significantly 
higher in patients with high vascular signals than in those with 
almost no vascular signal. Furthermore, CE-US may be a feasible 
technology for molecular imaging of the expression of VEGF receptor 
type 2 (VEGFR2) [58]. After UCAs conjugated with an anti-VEGFR2 
monoclonal antibody or an isotype control antibody were randomly 
injected into breast cancer cells implanted in athymic nude mice, the 
sonograms were analyzed by calculating the intensity amplitudes, 
and the tumor samples were harvested for the analysis of VEGFR2 
expression. The mean intensity amplitude caused by a backscatter 
of the retained VEGFR2-targeted UCA was significantly higher than 
that of the control UCA. This study showed that targeted CE-US may 
enable in vivo molecular imaging of VEGFR2 expression in the tumor 
vascular endothelium and may be used for non-invasive longitudinal 
evaluation of tumor angiogenesis in preclinical studies. It is expected 
that CE-EUS will be used to assess the efficacy of antitumoral 
agents in pancreatic cancer because of the feasibility of these new 
technologies using CE-US. 
One study reported the usefulness of CE-EUS in predicting the 
efficacy of chemotherapy in patients with inoperable pancreatic 
cancer prior to the actual chemotherapy [58]. Using images from the 
early image phase (10-40 seconds after injection of the contrast 
materials), researchers considered the vessel sign to be positive 
when large (diameter, ≥1 mm), irregular subepithelial intratumoral 
vessels flowing from the periphery to the center of the tumor were 
detected by CE-EUS. Patients with a positive vessel sign showed 
significantly longer overall survival and progression-free survival 
than patients with a negative vessel sign.
Discussion
Through technical innovations in EUS and the development of 
contrast agents, the use of CE-EUS has been expanded to many 
diseases. The various applications of CE-EUS include differentiating 
benign from malignant lesions of the pancreas, GB, LNs, and other 
their values are higher than those of other benign tumors [44]. 
Additionally, with the use of CE-EUS, irregular vessels that enter from 
the periphery to the center of the GIST can be visualized for high-
grade GISTs; thus, CE-EUS can be used to evaluate the malignant 
potential of GIST [45].
Lymph Nodes
CE-EUS plays an important role in the detection of lymph node 
(LN) metastasis. Although EUS-FNA is useful in the pathological 
confirmation of LN status, CE-EUS can be useful in cases of 
mediastinal and abdominal LNs that do not approach the aspiration 
yield [46,47]. CE-EUS can detect a filling defect, which is a typical 
sign of malignant lymphadenopathy, with a sensitivity of 100% 
and a specificity of 84% [46]. Furthermore, CE-EUS can be used 
to clearly observe the microvasculature of intra-abdominal lesions 
of undetermined origins, which can facilitate the differentiation 
of malignant from benign lesions, because of the homogeneous 
enhancement of benign lesions [48]. As such, it is expected that 
CE-EUS with respect to the LN status can be used for the N-staging 
of digestive tract tumors.
Other Diseases
Various clinical applications of vessel visualization by CE-EUS 
are being implemented. Color Doppler EUS and CE-EUS can 
be combined to evaluate the morphological and hemodynamic 
characteristics of visceral vascular diseases, which can be useful for 
the diagnosis of splanchnic artery disease [49]. It can also be used 
to determine the appropriate treatment of isolated mesenteric artery 
dissection [49]. In this report, it was suggested that the intimal 
flap and blood flow within the true lumen in patients with celiac 
artery dissection be evaluated with CE-EUS; further, it was reported 
that this information is useful in deciding the medical treatment 
or surgery. Enhanced vessels and the third echogenic layer of the 
esophageal wall can be visualized to detect perforating veins and 
periesophageal varices [50]. Cholecystoduodenal fistulas have also 
been detected by means of an enhancement of the gastrointestinal 
tract using CE-EUS [51].
Clinical Applications: Treatment Monitoring
Although no direct therapeutic procedure can be performed with it, 
CE-EUS serves as a monitoring tool for a range of disease entities. 
Many studies are being conducted to expand the role of CE-EUS in 
the evaluation of the effects of treatments of such diseases. One 
of the greatest strengths of CE-EUS, the visualization of vessel 
function, makes this possible. For the treatment of focal pancreatic 
lesions, EUS-guided pancreatic tissue ablation has been used [52-
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gastrointestinal lesions, as well as assessing the depth of invasion of 
esophageal, gastric, and GB cancers for tumor staging. Additionally, 
CE-EUS can indicate tumor neovascularization using contrast agents. 
CE-EUS imaging is useful in assessing and monitoring the efficacy of 
antiangiogenic agents, and allows molecular imaging by quantifying 
tumor perfusion.
CE-EUS is significantly more sensitive and accurate than 
conventional EUS in detecting the relatively hypovascular ductal 
adenocarcinomas of the pancreas due to its enhancement ability 
[4,5,25,28]. CE-EUS imaging improves the depiction of pancreatic 
tumors, enabling the detection of small lesions that may be 
uncertain in conventional EUS because of biliary stents or chronic 
pancreatitis [25]. In terms of the efficacy of CE-EUS and conventional 
EUS in preoperative T-staging of pancreatobiliary tumors, CE-EUS is 
more accurate than conventional EUS (rate of misdiagnosis: CE-EUS 
vs. EUS=7.6% vs. 23%) [37]. 
Additionally, the efficacy of CE-EUS in the differential diagnosis of 
small pancreatic tumors was superior to that of contrast-enhanced 
multidetector-row CT (MDCT) in two comparative studies [5,27]. 
Although CE-EUS and MDCT did not differ significantly in diagnostic 
ability with respect to all pancreatic masses, CE-EUS exhibited the 
highest sensitivity in differentiating between pancreatic ductal 
carcinoma and other tumors in pancreatic masses <2 cm in diameter 
(CE-EUS, 83%; EUS, 11%; MDCT, 50%) [5]. 
Occasionally, CE-EUS can differentiate small pancreatic carcinomas 
that cannot be detected by other imaging modalities [15,27]. In 
one study, seven ductal carcinomas and two neuroendocrine tumors 
showed hypoenhancement and hyperenhancement, respectively, 
on CH-EUS in 12 neoplasms that were not detected by MDCT [27]. 
CE-EUS may be a promising method to detect and characterize small 
pancreatic tumors that cannot be identified by other imaging tools 
[59]. Enhancement patterns demonstrated by CE-EUS during the 
subsequent vascular phase (e.g., arterial and venous phases) can be 
similar to MDCT [60].
An advantage of CE-EUS is its ability to assess the contrast 
enhancement patterns in real time with a substantially higher 
temporal resolution than other imaging modalities without the 
need to predefine scan time points or perform bolus tracking [60]. 
Furthermore, repeated administration of contrast agents during 
CE-EUS is possible due to the excellent patient tolerance of such 
agents.
However, although CE-EUS further improved the efficacy of 
EUS in terms of the characterization of target lesions by allowing 
visualization of microvessels and parenchymal perfusion, the analysis 
of the enhanced images is subjective and operator-dependent. 
To overcome these limitations, Inflow Time Mapping has been 
proposed as a new tool for an objective quantitative evaluation [7]. 
Three-dimensional CE-EUS may also be useful in reducing operator-
dependence because the enhanced images are obtained by the free-
hand movement of the endoscope during CE-EUS [8,9]. However, 
the clinical applications of these new techniques are at present 
restricted to case reports and a few studies; further large-scale 
studies are needed.
In conclusion, conceptual innovations and continuous technical 
developments have enabled CE-EUS to be used as a supplementary 
or additive tool with other cross-sectional and dynamic imaging 
modalities like computed tomography and magnetic resonance 
imaging.
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